Current and Evolving Understanding in Hypertrophic Cardiomyopathy - Cardiology Grand Rounds

Current and Evolving Understanding in Hypertrophic Cardiomyopathy - Cardiology Grand Rounds

MonteHeart Lectures via YouTube Direct link

AI, EKG, HCM

8 of 49

8 of 49

AI, EKG, HCM

Class Central Classrooms beta

YouTube videos curated by Class Central.

Classroom Contents

Current and Evolving Understanding in Hypertrophic Cardiomyopathy - Cardiology Grand Rounds

Automatically move to the next video in the Classroom when playback concludes

  1. 1 Current and Evolving Understanding in Hypertrophic Cardiomyopa
  2. 2 Hypertrophic Cardiomyopathy: Some simple math
  3. 3 Step 1: Multimodality imaging key in diagnosing HCM
  4. 4 Recognition of Apical aneurysms
  5. 5 LV Strain
  6. 6 NIH Sponsored HCMR Registry
  7. 7 Machine learning. LV shape and insights into pathophysiology
  8. 8 AI, EKG, HCM
  9. 9 Machine learning and HCM
  10. 10 Elicit LVOT Obstruction: Don't look, Won't find, Can't Tre
  11. 11 Stress Echo
  12. 12 Recognize typical and atypical variants of obstructive HC OCM without the H: Abnormal mitral subvalvular morphology
  13. 13 3 different flavors of "Atypical" LVOT obstruction
  14. 14 Differential diagnosis using multimodality imaging
  15. 15 Important to make the correct diagnosis
  16. 16 SCD risk stratification
  17. 17 Comparison of ESC vs. American Approach
  18. 18 ICD placement
  19. 19 HCM LGE Outcomes
  20. 20 Screening Echo vs. CMR in G+P-patients
  21. 21 Management in oHCM
  22. 22 Lifestyle considerations
  23. 23 Vigorous exercise and HCM: LIVE-HCM Trial
  24. 24 In oHCM, there are no prospective RCT (single or multicenter) compar a various FDA-approved medical therapies b invasive therapies vs. FDA-approved medical Rx c myectomy vs. alcohol ablation
  25. 25 Septal Reduction Therapy: One operation does not fit
  26. 26 Cleveland Clinic approach to Surgical LVOT obstructi
  27. 27 Alcohol septal ablation
  28. 28 Guidelines: Invasive therapies
  29. 29 Spectrum of oHCM management in USA
  30. 30 Expert Centers Have Markedly Better SRT Outcomes But Access to Specialty Centers Are Limited
  31. 31 Mavacamten Prevents Disease Phenotype in HCM Mice
  32. 32 Phase III RCTs: Testing Mavacamten vs. Placebo EXPLORER-HCM vs. VALOR-HCM
  33. 33 Mavacamten LTE study
  34. 34 Valor-HCM: 92% NYHA Class III 19 US HCM Centers
  35. 35 Primary endpoint and NYHA Class Improvement
  36. 36 Secondary Efficacy Endpoints
  37. 37 Favorable Cardiac Remodeling
  38. 38 A VALOR Mavacamten Story
  39. 39 LVEF and mavacamten: Implications in clinical practice
  40. 40 Clinical management of Camzyos (Mavacamten)
  41. 41 Gene-therapy: Adeno-associated Virus mediated
  42. 42 These new therapies are going to bring new logistic scenarios, assum long-term safety and efficacy
  43. 43 Symptomatic Nonobstructive HCM
  44. 44 Managing Arrhythmias Atrial fibrillation: A Bad Actor in HCM, especially oHCM
  45. 45 Management of AF
  46. 46 Genetic Testing in HCM
  47. 47 Genetics and long-term outcomes: SHARE registry!
  48. 48 Screening of asymptomatic first-degree relativ EKG and echo
  49. 49 Valsartan in Early Stage HCM: VANISH Trial

Never Stop Learning.

Get personalized course recommendations, track subjects and courses with reminders, and more.

Someone learning on their laptop while sitting on the floor.